

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS	RETINOID (TOPICAL)
BRAND NAME (generic)	TAZORAC (ALL TOPICAL) (tazarotene)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Tazorac (tazarotene) Cream

Tazorac Cream 0.05% and 0.1% are indicated for the topical treatment of plaque psoriasis.
Tazorac Cream 0.1% is also indicated for the topical treatment of acne vulgaris.

Tazorac (tazarotene) Gel

Tazorac Gel 0.05% and 0.1% are indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement.
Tazorac Gel 0.1% is also indicated for the topical treatment of mild to moderate facial acne vulgaris.

Limitations of Use

The safety of Tazorac Gel use on more than 20% body surface area has not been established.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of acne vulgaris
- OR**
- The requested drug is being prescribed for plaque psoriasis to treat less than 20 percent of the patient's body surface area
- AND**
- The patient has experienced an inadequate treatment response to at least one topical corticosteroid
[Note: The patient may continue to use a corticosteroid product (e.g., clobetasol, fluocinonide, mometasone, triamcinolone, etc.).]
- OR**
- The patient has experienced an intolerance to at least one topical corticosteroid
- OR**
- The patient has a contraindication that would prohibit a trial of topical corticosteroids

REFERENCES

1. Tazorac Cream [package insert]. Irvine, CA: Allergan, Inc; July 2017.
2. Tazorac Gel [package insert]. Irvine, CA: Allergan, Inc; April 2018.
3. Avage [package insert]. Irvine, CA: Allergan, Inc; July 2017.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed March 2020.
5. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed March 2020.
6. Menter A, Korman N, Elmets C, et al. Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis. *J Am Acad Dermatol*. 2009;60:643-659.

7. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol.* 2016; 74:945-73.
8. National Psoriasis Foundation. Fifth Edition of The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. <https://www.psoriasis.org/pocket-guide>. Accessed March 2020.